Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK109 in advanced solid tumors
NCT04547205Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pulocimab in solid tumor (advanced stage), sponsored by Akeso, Inc. Primary endpoint: Number of subjects experiencing dose-limiting toxicities at 4 weeks. Started Jun 2020; status: completed.
02
Drugs
pulocimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04547205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547205.